Ipsen

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure®/ Dysport® (abobotulinumtoxinA)

Lausanne, Switzerland:  Galderma today announced top-line results from a Phase 2 study on the impact of dose escalation on the…

Read More »